A Retrospective Analysis of Vancomycin Pharmacokinetics in Korean Neonates

다국어 초록 (Multilingual Abstract)

Background : Vancomycin is commonly used in neonatal intensive care units (NICU) for the treatment of gram-positive bacterial infections. The aims of this study were to determine the pharmacokinetic parameters of vancomycin in Korean neonates and to assess the percentage of neonates who reached a therapeutic level (trough concentrations of 10 to 20 mg/L) with empirical vancomycin dosing according to the Neofax􀋓.
Methods : This retrospective study reviewed data from 81 neonates admitted to the NICU. The elimination rate constant (Ke), half-life (T1/2), clearance (CL), and the extrapolated trough and peak levels were calculated using first-order pharmacokinetics and a one-compartment model.
Results : Only 21% of the patients achieved therapeutic trough levels (10 to 20 mg/L) with initial dosing according to the Neofax􀋓. Vancomycin clearance was significantly correlated with postmenstrual age (PMA), postnatal age (PNA), weight, and serum creatinine (SCr) level. The recommended dosing regimen in neonates 27 weeks PMA was 10~15 mg/kg q12hr. For neonates in the 27 to 30 week PMA range, the recommended regimen was 15 mg/kg q12hr or 10 mg/kg q8hr for PNA 0~14 days, 10~13 mg/kg q8hr for PNA 14 days with SCr 0.6 mg/dL, and 10~15 mg/kg q12hr for PNA 14 days with SCr 0.6 to 1.5 mg/dL. For neonates in the 30 to 37 week PMA range, the recommended regimen was 10~13 mg/kg q8hr for PNA 0~14 days, 13 mg/kg q8hr or 10 mg/kg q6hr for PNA 14 days with SCr 0.6 mg/dL, and 15 mg/kg q12hr or 10 mg/kg q8hr for PNA 14 days with SCr 0.6 to 1.5 mg/dL. For neonates in the 37 to 44 week PMA range, the recommended regimen was 10~13 mg/kg q8hr for PNA 0~7 days, 13~15 mg/kg q6hr for PNA 7 days with SCr 0.6 mg/dL, and 13 mg/kg q8hr or 10 mg/kg q6hr for PNA 7 days with SCr 0.6 to 1.5 mg/dL. Sixty-three percent (51/81) of the neonates reached a therapeutic level with the new dosing regimen.
Conclusions : The Neofax􀋓 vancomycin initial dosing regimen is insufficient for Korean neonates.
Further studies are needed to validate the new dosing regimen suitable for achieving target therapeutic levels in Korean neonates.

참고문헌 (Reference)

1 도현정, "신생아에서의 Vancomycin 용량 가이드라인 적절성 평가" 한국병원약사회 33 (33): 130-140, 2016

2 Sorrell TC, "Vancomycin therapy for methicillin-resistant Staphylococcus aureus" 97 (97): 344-350, 1982

3 Rybak M, "Therapeutic monitoring of vancomycin in adult patients : a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America and the Society of Infectious Diseases Pharmacists" 66 (66): 82-98, 2009

4 Choi SJ, "The study on vancomycin pharmacokinetics and dosing guideline in Korean neonates" 6 (6): 7-13, 1996

5 Petrie K, "Neonatal vancomycin trough level audit using British National Formulary for Children dosing" 100 (100): F278-F279, 2015

6 Yaffe SJ, "Neonatal and pediatric pharmacology" Wolters Kluwer/Lippincott Williams & Wilkins Health 2010

7 Young T., "NEOFAX" Thomson Reuters 2011

8 Gerald B Merenstein, "Merenstein & Gardner’s handbook of neonatal intensive care" MOSBY 2011

9 Sinkeler FS, "Inadequate vancomycin therapy in term and preterm neonates : a retrospective analysis of trough serum concentrations in relation to minimal inhibitory concentrations" 14 (14): 193-, 2014

10 Kim JS, "Clinical pharmacokinetics of vancomycin in Korean neonates" 13 (13): 222-227, 1996

11 Murphy JE, "Clinical pharmacokinetics" American Society of Health-System Pharmacists 2012

12 Ringenberg T, "Achievement of therapeutic vancomycin trough serum concentrations with empiric dosing in neonatal intensive care unit patients" 34 (34): 742-747, 2015

13 Vandendriessche A, "A Prospective validation of neonatal vancomycin dosing regimens is urgently needed" 76 : 51-57, 2014